High-dose therapy plus BMT improve survival in follicular lymphoma patients.
At a median follow-up of 6.5 years, the estimated 10-year survival of 37 patients who underwent HCRC plus ABMT was 86% (97%, if lymphoma-related deaths were excluded). Two patients died of early transplant-related causes, 2 died of late acute leukemia, and 10 patients relapsed after transplantation. The estimated probability of death and relapse at 10 years was 14% and 30%, respectively, in the transplanted group-percentages that were considerably lower than the historical cohort of 188 similar patients. In addition, while survival in reference patients was adversely affected by high initial tumor burden and incomplete response to chemotherapy, it was not affected by these parameters in patients receiving HCRC plus ABMT. (Blood 2001;97:404-409.)
|Printer friendly Cite/link Email Feedback|
|Comment:||High-dose therapy plus BMT improve survival in follicular lymphoma patients.|
|Date:||Mar 16, 2001|
|Previous Article:||Few infectious complications after BMT for breast cancer.|
|Next Article:||Pretransplant disease severity influences success of liver transplant.|